AZ-LIMELIGHT-NETWORKS
29.5.2019 15:13:04 CEST | Business Wire | Press release
Limelight Networks, Inc. (Nasdaq: LLNW) , a leading provider of edge cloud services, today announced that MX Player used Limelight’s Content Delivery Network (CDN) to provide a seamless and a broadcast quality experience to millions of viewers watching the 2019 Lok Sabha Elections. More than 900 million Indian citizens were eligible to vote, making it the largest election in the world.
Investments over the last few years have helped Limelight emerge as one of the largest content delivery networks in the country. Limelight Networks has been working with MX Player and other content originators and distributors to address their global content delivery needs. The company delivers rich content such as video, games, and software into India for its global customers. At the same time, Limelight has been helping Indian media companies deliver content to their global customers.
At its peak, traffic was flowing at 10 times the normal volume during the election. Using Limelight’s CDN, MX Player handled anticipated traffic spikes and successfully managed to provide a seamless and broadcast-quality experience on millions of connected devices to their Indian and global customers.
"With 100 Million Daily Active Users and 275 Million Monthly Active Users, MX Player is the largest video platform from India. We partnered with Limelight Networks to deliver high performance video to our large user base. On May 23, the day elections results came out, we saw a 10x spike from our usual traffic trend. I’m very happy to see that the teams from both sides have integrated a really robust system, which was able to deliver billions of request on this day smoothly and successfully,” said Vivek Jain, Chief of Product, Tech & Operations, MX Player
“As a long time CDN and video delivery partner, Limelight Networks was honored for the opportunity to support this milestone event. We’ll continue to scale and innovate on our journey with MX Player and our other media customers and keep providing high quality services to their online audiences,” said Ashwin Rao, Director, India at Limelight Networks.
About MX Player:
With over 75 million Daily Active Users
(DAUs) – MX Player is the largest entertainment platform in the country,
present on 1 out of every 2 smartphones. Defining “everytainment” for
viewers with entertainment that suits every mood, it currently operates
on an ad supported model and is a free to use app for premium content.
MX Player provides users a wide online streaming library of over 100,000
hours of licensed content, across 10 languages and an exciting slate of
MX Original Series with genres ranging across drama, comedy, reality and
romance. From the stable of Times Internet (the digital venture of Times
of India, India's largest media and entertainment group), MX Player has
consistently ranked amongst the top 10 Android apps since 2012 and is
available across Android, iOS and Web.
About Limelight
Limelight Networks, Inc. (NASDAQ: LLNW), a
leading provider of digital content delivery, video, cloud security, and
edge computing services, empowers customers to provide exceptional
digital experiences. Limelight’s edge services platform includes a
unique combination of global private infrastructure, intelligent
software, and expert support services that enable current and future
workflows. For more information, visit www.limelight.com
,
follow us on Twitter
,
Facebook
,
and LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005570/en/
Contact:
SHIFT Communications Stephanie Epstein, 617-779-1845 Limelight@shiftcomm.com or Investor Inquiries: ir@limelight.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom